Armata Pharmaceuticals Inc.
(NYSE:ARMP) stock is trading higher on Monday after the company announced significant clinical, regulatory, manufacturing, and operational progress supporting the advancement of its lead therapeutic candidate, AP-SA02.
The late clinical-stage biotechnology business is moving the intravenously administered Staphylococcus aureus multi-phage product toward a pivotal Phase 3 superiority study set to begin in the second half of 2026.
The upcoming trial is designed to support a future Biologics License Application for the treatment of complicated bacteremia caused by methicillin-sensitive (MSSA) or methicillin-resistant (MRSA) strains.
Read Also: Why UnitedHealth Can't Stop Saying One Word: 'Restless' Regulatory Alignment And Operational Readiness Armata said it submitted the complete Phase 3 protocol to the U.S.
